Mind Medicine Mindmed Inc (MNMD) Stock Price, Quote & News

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: www.mindmed.co

Address:

One World Trade Center, Suite 8500, New York, United States

MichaelNaussCMT Jul. 6 at 8:45 PM

$MNMD $50

0 · Reply

Bulltrader988 Jul. 6 at 6:49 PM

$MNMD with $CMPS $CYBN $MIRA 👃👀 https://www.wsj.com/health/pharma/psychedelic-drugs-investment-maha-f4b7dff0

0 · Reply

Tom678 Jul. 6 at 6:37 PM

$ATAI $CYBN $MNMD exactly, tomorrow Im buying more shares . Don’t want to fall behind . This is literally calling me

0 · Reply

brbrown Jul. 6 at 3:52 PM

$MNMD

0 · Reply

MichaelNaussCMT Jul. 6 at 2:55 PM

$MNMD

0 · Reply

twiggs462 Jul. 6 at 1:51 PM

$ATAI $MNMD $CMPS The MAHA Movement Loves Psychedelics. Should Wall Street? https://www.wsj.com/health/pharma/psychedelic-drugs-investment-maha-f4b7dff0

0 · Reply

leLu83 Jul. 6 at 5:38 AM

$ATAI 💬 is the psychedelic mothership. Deepest pipeline Backed by Thiel, Angermayer Holds CMPS stake No RS, no convertibles, no PR pump clowns Real leadership, real R&D $CYBN and $MNMD? Just satellites orbiting the hype. #atai #mothership #psychedelics #sriniwins #bagfreezone

0 · Reply

leLu83 Jul. 6 at 5:21 AM

$MNMD 🔥 “Thick as Thieves”: The Barrow–Drysdale Blueprint Move Doug (CYBN) Robert (MNMD) 💰 Raised 9-figures $500M toxic convertibles $100M+ ATM & shelf offerings 🔃 Reverse Split Rug 1-for-38 1-for-15 🧪 No Phase 3 Started CYB003 only Phase 2 MM120 still Phase 2 📉 Shareholder Value Obliterated Obliterated 🕵️‍♂️ Low Insider Buying Zero real buys Zero buys post-RS 🤡 PR Spin > Substance “Best MADRS data ever” “LSD changed everything” 🧠 Their Strategy Is Not Drug Development — It’s Capital Extraction: Overpromise results Reverse split to enable financing Dilute into PR cycles Let “institutional partners” (read: death spiral lenders) convert and dump Collect comp, rinse, repeat

1 · Reply

McGuireTO Jul. 6 at 1:29 AM

$MNMD has a pretty heavy overhead supply, but the daily chart is looking good for a bull break, and this chart will likely benefit from ATAI monthly trend change as a sector sympathy play. Heavy supply remains above until $11, and moderate supply through to $20, after which there are not many bag-holders left to work through. https://www.tradingview.com/chart/MNMD/JZRVj5Am-Anticipating-MNMD-bull-break-but-large-overhead-supply-remains/

1 · Reply

Jersey1134 Jul. 6 at 12:50 AM

$MNMD Nice move

0 · Reply

MindMed Announces New Employee Inducement Grants

May 28, 2025, 7:00 AM EDT - 5 weeks ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 5 weeks ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 13, 2025, 7:00 AM EDT - 7 weeks ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 2 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 2 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 2 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 2 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 3 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 4 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 4 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 4 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 4 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 5 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 5 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 7 months ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 7 months ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 7 months ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 7 months ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 7 months ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 8 months ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 13, 2024, 7:00 AM EST - 8 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 10, 2024, 9:55 AM EST - 8 months ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 8 months ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 8 months ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 9 months ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Sep 4, 2024, 7:00 AM EDT - 10 months ago

MindMed to Participate in September Investor Conferences

Aug 15, 2024, 12:30 PM EDT - 11 months ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Aug 13, 2024, 11:21 AM EDT - 11 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:44 AM EDT - 11 months ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:01 AM EDT - 11 months ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

Aug 13, 2024, 7:00 AM EDT - 11 months ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 12, 2024, 12:47 PM EDT - 11 months ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:12 PM EDT - 11 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Aug 9, 2024, 8:44 AM EDT - 11 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Aug 9, 2024, 6:00 AM EDT - 11 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Aug 7, 2024, 2:29 PM EDT - 11 months ago

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

Aug 6, 2024, 4:01 PM EDT - 11 months ago

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 6, 2024, 7:00 AM EDT - 11 months ago

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Jul 17, 2024, 7:00 AM EDT - 1 year ago

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Jun 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

Jun 21, 2024, 7:00 AM EDT - 1 year ago

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Jun 5, 2024, 11:46 AM EDT - 1 year ago

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

May 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Conferences

May 23, 2024, 12:15 PM EDT - 1 year ago

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

CMPS

May 9, 2024, 4:01 PM EDT - 1 year ago

MindMed to Participate at May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

MichaelNaussCMT Jul. 6 at 8:45 PM

$MNMD $50

0 · Reply

Bulltrader988 Jul. 6 at 6:49 PM

$MNMD with $CMPS $CYBN $MIRA 👃👀 https://www.wsj.com/health/pharma/psychedelic-drugs-investment-maha-f4b7dff0

0 · Reply

Tom678 Jul. 6 at 6:37 PM

$ATAI $CYBN $MNMD exactly, tomorrow Im buying more shares . Don’t want to fall behind . This is literally calling me

0 · Reply

brbrown Jul. 6 at 3:52 PM

$MNMD

0 · Reply

MichaelNaussCMT Jul. 6 at 2:55 PM

$MNMD

0 · Reply

twiggs462 Jul. 6 at 1:51 PM

$ATAI $MNMD $CMPS The MAHA Movement Loves Psychedelics. Should Wall Street? https://www.wsj.com/health/pharma/psychedelic-drugs-investment-maha-f4b7dff0

0 · Reply

leLu83 Jul. 6 at 5:38 AM

0 · Reply

leLu83 Jul. 6 at 5:21 AM

1 · Reply

McGuireTO Jul. 6 at 1:29 AM

1 · Reply

Jersey1134 Jul. 6 at 12:50 AM

$MNMD Nice move

0 · Reply

MichaelNaussCMT Jul. 5 at 8:30 PM

$ATAI $CMPS $MNMD $50

0 · Reply

twiggs462 Jul. 5 at 8:12 PM

$MNMD $ATAI $CMPS https://x.com/SecVetAffairs/status/1940727323852001691?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1940727323852001691%7Ctwgr%5E1ae08b2fbc0db2e9a3ea065a88e7126b397b4256%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fwww.marijuanamoment.net%2Ftrumps-va-secretary-is-particularly-proud-of-psychedelic-research-aimed-at-helping-veterans-with-ptsd%2F

0 · Reply

MichaelNaussCMT Jul. 5 at 6:16 PM

$MNMD 50

0 · Reply

Mjcwo Jul. 5 at 4:12 PM

$GLMD $MDCX $MNMD all gems….💎

0 · Reply

topstockalerts Jul. 5 at 1:50 PM

$MNMD double digits ahead??

0 · Reply

TradingLaboratory Jul. 5 at 12:57 AM

$MNMD

0 · Reply

DCRMIA Jul. 4 at 10:17 PM

It is anticipated that the value of $MNMD may experience a significant increase in the near future🚀📈🆙️ The FDA has not yet issued emergency use authorizations (EUAs) for psychedelic substances as of July 2025. However, there is significant speculation and growing support within the U.S. government for this possibility. Potential Effects of FDA EUA on MNMD:

0 · Reply

WeHaveHighHopes Jul. 4 at 9:03 PM

$MNMD To High To Die.

1 · Reply

MichaelNaussCMT Jul. 4 at 8:53 PM

$MNMD #1 trending

0 · Reply

YouVSYou Jul. 4 at 8:48 PM

$MNMD https://x.com/justinss55/status/1941165725563097373?s=46

0 · Reply

leLu83 Jul. 4 at 8:44 PM

$MNMD I am currently formulating a Bull exit strategy. If this post receives 10 likes ill share where the stock is headed and best ways to exit.

0 · Reply

leLu83 Jul. 4 at 8:35 PM

$CYBN $MNMD Trust me these little dorks read all these messages. Here is whats behind the curtain at these companies. Vote the Board out. They control everything. Vote your shares. Unite together as a voting bloc. They only report to the banks because they are united. 🪤 Who these broke front men Really Are: Operators, not founders Put in place to raise funds, spin PR, and kick the can Boards use them as buffer zones between angry retail and the real puppet masters Neither has a track record of: Taking a compound to market Delivering long-term shareholder value Buying shares with their own money

1 · Reply

Market Cap	541.72M
Revenue (ttm)	0.00
Net Income (ttm)	-108.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.10

Volume	583,900
Avg Vol	1,144,340
Day's Range	N/A - N/A
Shares Out	75.55M
Stochastic %K	87%
Beta	2.45
Analysts	Strong Sell
Price Target	$25.00